Bristol Myers Squibb Company $BMY Shares Sold by Cooper Financial Group

Cooper Financial Group trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 17.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,031 shares of the biopharmaceutical company’s stock after selling 2,821 shares during the period. Cooper Financial Group’s holdings in Bristol Myers Squibb were worth $603,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. MBA Advisors LLC increased its holdings in shares of Bristol Myers Squibb by 13.0% during the 2nd quarter. MBA Advisors LLC now owns 6,766 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 776 shares during the last quarter. Emerald Advisors LLC increased its holdings in shares of Bristol Myers Squibb by 18.4% during the 2nd quarter. Emerald Advisors LLC now owns 19,293 shares of the biopharmaceutical company’s stock worth $893,000 after buying an additional 2,995 shares during the last quarter. HCR Wealth Advisors increased its holdings in shares of Bristol Myers Squibb by 4.5% during the 2nd quarter. HCR Wealth Advisors now owns 10,671 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 458 shares during the last quarter. Janney Capital Management LLC increased its holdings in shares of Bristol Myers Squibb by 1.7% during the 2nd quarter. Janney Capital Management LLC now owns 40,993 shares of the biopharmaceutical company’s stock worth $1,898,000 after buying an additional 695 shares during the last quarter. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH increased its holdings in shares of Bristol Myers Squibb by 19.7% during the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 5,156 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 848 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a report on Tuesday, August 5th. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Finally, Citigroup decreased their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $56.38.

Bristol Myers Squibb Trading Up 5.1%

BMY opened at $47.39 on Thursday. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The stock has a market capitalization of $96.47 billion, a PE ratio of 19.11, a P/E/G ratio of 2.31 and a beta of 0.33. The firm’s fifty day moving average price is $46.49 and its 200 day moving average price is $48.85.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the business earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.2%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.09% of the company’s stock.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.